Kaposi's sarcoma and non-hodgkin's lymphoma incidence trends in AIDS clinical trial group study participants

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 21, Issue 4 SUPPL., 1999, Pages

  Rabkin, Charles S ^a   Testa, Marcia A ^b   Huang, Jie ^b   Von Roenn, Jamie H ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

AIDS; Antiretroviral therapy; Kaposi's sarcoma; Non Hodgkin's lymphoma; Protease inhibitors

Indexed keywords

DIDANOSINE; FOSCARNET; GANCICLOVIR; INDINAVIR; NEVIRAPINE; VALACICLOVIR; ZALCITABINE; ZIDOVUDINE;

AIDS RELATED COMPLEX; ANTIVIRAL ACTIVITY; CANCER PREVENTION; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; VIRUS INHIBITION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CLINICAL TRIALS; CYTOMEGALOVIRUS RETINITIS; FOSCARNET; GANCICLOVIR; HIV INFECTIONS; HUMANS; INCIDENCE; INDINAVIR; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; RETROSPECTIVE STUDIES; SARCOMA, KAPOSI;

CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0033179409     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (8)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team [see comments]. N Engl J Med 1997;337:725-33.
2. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy [see comments]. JAMA 1998;279:450-4.
3. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs: implications for potential therapy. J Clin Invest 1997;99:2082-6.
4. Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 1996;10:1101-5.
5. Jones JL, Hanson DL, Chu SY, Ward JW, Jaffe HW. AIDS-associated Kaposi's sarcoma [letter; comment]. Science 1995;267: 1078-9.
6. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997;11:1731-8.
7. Glesby MJ, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis 1996;173:1477-80.
8. Selik RM, Starcher ET, Curran JW. Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS 1987;1:175-82.